News Search Results
Apr 30, 2026, 07:38 ET Primeira toxina botulínica recombinante tipo A do mundo é aprovada para comercialização na China, em avanço tecnológico liderado pela Claruvis Pharmaceutical
saúde em todo o mundo."Sobre a Claruvis Pharmaceutical Co., Ltd.A Claruvis Pharmaceutical Co., Ltd., subsidiária da MingMed Biotechnology, é uma biofarmacêutica orientada pela inovação e dedicada à pesquisa, ao desenvolvimento, à fabricação e à comercialização de produtos à base de
More news about: Claruvis Pharmaceutical
Apr 30, 2026, 07:00 ET Brenig Therapeutics to Present Hybrid AI Drug Discovery Platform at Keystone Symposia Computational Advances in Drug Discovery
BOSTON and SAN DIEGO, April 30, 2026 /PRNewswire/ -- Brenig Therapeutics Inc. (Brenig), a clinical-stage biotechnology company advancing best-in-class therapies for neurodegenerative, neuroinflammatory, and cardiometabolic diseases, today announced that Alexei
More news about: Brenig Therapeutics Inc
Apr 30, 2026, 06:45 ET Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Apr 30, 2026, 06:30 ET Immunic to Participate in Investor and Medical Conferences in May
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor and
More news about: Immunic, Inc.
Apr 30, 2026, 05:00 ET Glyceryl Glucoside Market worth $39.0 million by 2031- Exclusive Report by MarketsandMarkets™
AG (Germany), YR Chemspec (China), Beiersdorf AG (Germany), Puri Pharma (China), Storm Chemical (China), Incospharm (South Korea), Nanjing DASF Biotechnology Co., Ltd (China), Seebio Biotech (Shanghai) Co., Ltd (China), Woosung CNT Co., Ltd. (South Korea), Sino Lion Chemical Co., Ltd. (China), Soho Aneco
More news about: MarketsandMarkets
Apr 30, 2026, 04:57 ET CMEF 2026 khép lại tại Thượng Hải: sân khấu toàn cầu cho những đột phá và xu hướng tương lai ngành y tế
nghệ Sinh học Quốc tế Hồng Kông (BIOHK) 2026: từ ngày 9–12 tháng 9, tại Trung tâm Hội nghị và Triển lãm Hồng Kông, đồng tổ chức với Hong Kong Biotechnology Organization;Hội chợ CMEF lần thứ 94 và chuỗi triển lãm đồng thời: từ ngày 21–24 tháng 10, tại Capital International Exhibition
More news about: CMEF
Apr 30, 2026, 04:00 ET Biotech and Olive Agriculture Veterans Launch Oleocan™, Delivering Broad-Spectrum EVOO Polyphenols Without the Calories or Constraints
Founded by Pat Condon, a biotechnology and finance veteran, and Michael Paz, an olive grower and olive harvesting specialist, Oleocan was created to address a practical and scientific
More news about: Earthborn Alternatives DBA OLEOCAN
Apr 30, 2026, 02:38 ET Weltweit erstes neues Arzneimittel mit rekombinantem Botulinumtoxin Typ A erhält Marktzulassung in China: eine von Claruvis Pharmaceutical vorangetriebene technologische Revolution
bereitzustellen."Informationen zu Claruvis PharmaceuticalClaruvis Pharmaceutical Co., Ltd., eine Tochtergesellschaft von MingMed Biotechnology, ist ein innovationsgetriebenes biopharmazeutisches Unternehmen, das sich auf die Forschung, Entwicklung, Herstellung und Vermarktung rekombinanter
More news about: Claruvis Pharmaceutical
Apr 29, 2026, 23:13 ET D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
SHANGHAI, April 29, 2026 /PRNewswire/ -- D3 Bio Inc., a global clinical-stage biotechnology company dedicated to developing innovative oncology therapeutics, today announced new phase 2 clinical data from its lead asset elisrasib (D3S-001),
More news about: D3 Bio
Apr 29, 2026, 22:35 ET Robbins LLP Reminds MEDP Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Medpace Holdings Inc.
Medpace is a clinical contract research organization (CRO) focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.
More news about: Robbins LLP
Apr 29, 2026, 22:15 ET CMEF 2026 wraps up in Shanghai: a global stage for medical breakthroughs and future trends
Lumpur Convention Centre, Malaysia;Hong Kong International Biotechnology Conference and Exhibition (BIOHK) 2026: September 9–12, Hong Kong Convention and Exhibition Centre, co-organized with the Hong Kong Biotechnology Organization;The 94th CMEF and concurrent series exhibitions:
More news about: CMEF
Apr 29, 2026, 21:58 ET Finland and Australia looking to join forces on quantum technologies
across multiple technology readiness levels in areas including quantum sensing, communications and computing, and quantum-enabled applications in biotechnology and energy.Further information VTT Technical Research Centre of Finland LtdAnu Kärkkäinen, Research Manager,
More news about: VTT Info
Apr 29, 2026, 21:56 ET CMEF 2026 wraps up in Shanghai: a global stage for medical breakthroughs and future trends
Lumpur Convention Centre, Malaysia;Hong Kong International Biotechnology Conference and Exhibition (BIOHK) 2026: September 9–12, Hong Kong Convention and Exhibition Centre, co-organized with the Hong Kong Biotechnology Organization;The 94th CMEF and concurrent series exhibitions:
More news about: CMEF
Apr 29, 2026, 20:10 ET Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
American Diabetes Association).About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Apr 29, 2026, 19:00 ET Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca
CAMBRIDGE, Mass., April 29, 2026 /PRNewswire/ -- Pinetree Therapeutics, Inc. ("Pinetree"), a biotechnology company pioneering next-generation targeted protein degradation approaches for cancer and other serious diseases, today announced that AstraZeneca
More news about: PineTree Therapeutics
Apr 29, 2026, 14:24 ET Rubin Rudman Partner Matthew Joyce Named a 2026 Go To Tax Lawyer by Massachusetts Lawyers Weekly
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; hospitality companies; regulated industries, public entities and municipalities; insurance companies
More news about: Rubin Rudman
Apr 29, 2026, 10:05 ET Vascular Endothelial Growth Factor Inhibitors Market to Reach USD 33.5 Billion by 2036, Driven by Rising Cancer Burden, Biosimilar Expansion, and Shift Toward Subcutaneous Therapies
infrastructure.Key Buyers and Procurement TrendsPrimary stakeholders include:Pharmaceutical companiesBiotechnology firmsHospitals and specialty clinicsBuyers prioritize:Proven clinical efficacy and safetyCost-effective
More news about: Future Market Insights
Apr 29, 2026, 09:15 ET WACKER to present personal care ingredient innovations at NYSCC Suppliers' Day 2026
range of end uses. This framing is consistent with NYSCC's 2026 programming, which is placing added attention on topics such as sustainability and biotechnology in personal care.Visit WACKER at NYSCC Suppliers' Day 2026 in New York and stop by Booth #343 to meet with WACKER representatives
More news about: Wacker Chemical Corp.
Apr 29, 2026, 09:15 ET Expression Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for Investigational Stem Cell Therapy for Hemophilia A
are building."ABOUT EXPRESSION THERAPEUTICSExpression Therapeutics, Inc., based in Atlanta, Georgia, is a clinical-stage biotechnology company advancing an investigational autologous stem cell therapy for hemophilia A and investigational cell therapies for neuroendocrine tumors
More news about: Expression Therapeutics, Inc.
Apr 29, 2026, 09:10 ET Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Mexican Institute of Industrial Property (IMPI) has issued Patent
More news about: Anixa Biosciences, Inc.
Apr 29, 2026, 09:00 ET Infinite Epigenetics Acquires Tally Health to Accelerate the Future of Epigenetics-Driven Health and Longevity
Tally Health®, a biotechnology company pioneering consumer-focused longevity solutions. Tally Health brings cutting-edge science closer to everyday life by helping people better
More news about: TruDiagnostic
Apr 29, 2026, 09:00 ET Kytopen, T-CURX, and the Fraunhofer IZI Establish Center of Excellence to Develop Advanced, Non-viral Cell Therapies
across a range of cell types, payloads, and therapeutic applications. Kytopen has recently disclosed strategic partnerships with industry-leading biotechnology companies, contract development and manufacturing organizations (CDMOs), and cell therapy-focused medical centers. Kytopen continues to engage strategic
More news about: Kytopen
Apr 29, 2026, 08:59 ET CounterX Therapeutics Invited to Present at Science2Startup
fentanyl overdose crisis. "We are excited to participate in S2S and be a part of this exclusive symposium for a select group of cutting-edge biotechnology companies," said Shawn Iadonato, Chief Executive Officer of CounterX Therapeutics. "This event provides an excellent platform to connect with multiple
More news about: CounterX Therapeutics
Apr 29, 2026, 08:56 ET NanoMosaic to Showcase the FDA/CBER AMT Designated Analytics Platform at ASGCT 2026
expedited development pathways through NanoMosaic's FDA/CBER AMT designation.About NanoMosaicNanoMosaic Inc. is a pioneering biotechnology company developing innovative tools and technologies for multiomic biomarker detection and analysis. The company's flagship product, the NanoMosaic
More news about: NanoMosaic
Apr 29, 2026, 08:15 ET Vivacta Bio Closed Series A and Series A+ Financing of Over US$50 Million
SHANGHAI, April 29, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta" or "Vivacta Bio"), an innovative biotechnology company focused on revolutionizing in vivo CAR-T therapies, announces the
More news about: Vivacta Biotechnology (Shanghai) Co., Ltd.